European Patent Grants for IMP731 Antibody
(firmenpresse) - SYDNEY, AUSTRALIA -- (Marketwired) -- 08/24/16 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces the granting of patent number 2142210 entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" by the European Patent Office.
The patent relates to Prima''s IMP731 antibody (originally developed by Immutep SAS). The granted claims provide protection for specific sequences of anti-LAG-3 antibodies and their use in depleting LAG-3+ T cells by complement dependent cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC).
Rights for the development of the IMP731 antibody were granted in December 2010 to GSK, which has commenced first-in-human clinical trials of the proprietary antibody (GSK2831781) derived from IMP731.
IMP731 and GSK2831781 are designed to specifically deplete potentially pathogenic, recently activated, LAG-3 expressing T cells which are enriched at the disease site in T-cell driven immuno-inflammatory disorders and should spare other T-cells which may be necessary for other functions.
Under the terms of the 2010 agreement between Immutep and GSK, GSK has responsibility for all development and associated costs for GSK2831781. Prima BioMed may receive payments and potential milestones totalling up to £ 64 million and is eligible for single-digit, tiered royalties if all objectives are achieved.
A Phase 1, first-in-human clinical study of GSK2831781 for the treatment of autoimmune diseases has commenced and further information may be obtained at .
Prima BioMed is listed on the Australian Securities Exchange, and on the NASDAQ in the US. For further information please visit .
Mr. Matthew Gregorowski
Citadel-MAGNUS
+61 (2) 8234 0100
Matthew Beck
The Trout Group LLC
+1 (646) 378-2933
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 24.08.2016 - 18:34 Uhr
Sprache: Deutsch
News-ID 1454411
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SYDNEY, AUSTRALIA
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 203 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"European Patent Grants for IMP731 Antibody
"
steht unter der journalistisch-redaktionellen Verantwortung von
Prima BioMed Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
